<DOC>
	<DOCNO>NCT00405860</DOCNO>
	<brief_summary>Microscopic polyangiitis ( MP ) primary systemic vasculitis predominantly affect small blood vessel . Following widespread introduction ANCA testing , primary systemic vasculitis ( SV ) , Wegener ? granulomatosis ( WG ) microscopic polyangiitis ( MP ) appear frequent previously think ( see definition Appendix 6 ) . In addition , existence early organ-limited form disease , renal-limited vasculitis ( RLV ) clearly recognize . Their annual incidence exceed 20 per million per year account least 5 % cause end stage renal failure . The two disease share many feature histology , serology response treatment , point similarity pathogenesis , justified common approach management . The standard treatment corticosteroid ( CS ) cyclophosphamide ( CYC ) usually effective control active disease continue treatment necessary prevent disease relapse . Due cumulative toxicity associate CYC treatment , alternative look . Mycophenolate mofetil ( MMF ) use treat patient variety immune-mediated nephritides , include ANCA-associated vasculitis , less toxicity CYC variable outcome . The present trial examine whether substitution oral CYC oral MMF equally efficient induction remission less adverse effect case MP mild moderate renal involvement . All patient receive regimen oral prednisone + MMF . Prednisone taper stop 24 week MMF continue total 18 month unless worsen persistent disease . The trial end 18 month .</brief_summary>
	<brief_title>CellCept p-ANCA Vasculitis</brief_title>
	<detailed_description>1 . Patients receive I.V . methylprednisone , I.V . dexamethazone , oral prednisone oral MMF therapy outline table 2 . 2 . MMF initiate within first 1-2 week start steroid . Patients receive CellCept , 750 mg po b.i.d first week . Dose increase 1000 mg po b.i.d second week , thereafter , accord blood level patient tolerance . Target blood level 1 ? 3.5 &amp; # 61549 ; g/ml . Treatment total 18 month . This base publish dose-dependent adverse effect profile transplant patient ( 31-32 ) report low dos ineffective shorter course ( less 6 month ) result relapse failure therapy ( 25 ) . Dose reduce patient tolerate MMF dose . 2 ) Relapse treatment follow guideline relapse regimen . 3 ) After 18 month , medication taper full stop unless disease active grumbling . 4 ) Pneumocystis pneumonia prophylaxis use trial ( sulfamethoxazole/trimethoprim , Dapsone Mepron allergic sulfa ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Active microscopic polyangiitis 2 . Active urinary sediment ( &gt; 25 rbc/hpf , red cell cast dysmorphic red cell ) 3 . Renal biopsy compatible diagnosis microscopic polyangiitis , diagnosis demonstrate presence hematuria , proteinuria , dysmorphic red blood cell , / red blood cast biopsy contraindicate . 4 . Positive pANCA ( MPO ELISA ) 5 . Serum creatinine &lt; 3.0mg/dl . 6 . Age 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>